防治ASCVD的调脂治疗新靶点：血管生成素样蛋白3

李勇; 谢坤

doi:10.13201/j.issn.1001-1439.2021.09.001

防治ASCVD的调脂治疗新靶点：血管生成素样蛋白3

李勇^,,
谢坤

- 复旦大学附属华山医院心内科(上海, 200040)

详细信息

通讯作者: 李勇,E-mail:liyong606@126.com

中图分类号: R543

收稿日期: 2021-07-20

Angiopoietin-like protein 3: a novel target of lipid-lowering therapy in ASCVD

LI Yong^,,
XIE Kun

- Department of Cardiology, Huashan Hospital Affiliated to Fudan University, Shanghai, 200040, China

More Information

Corresponding author: LI Yong, E-mail: liyong606@126.com

Received Date: 20 July 2021

摘要

摘要: 血管生成素样蛋白(ANGPTL3)是继PCSK9抑制剂之后,调脂领域新的研究靶点。目前针对这一新兴靶点的治疗方式多样,除单克隆抗体外,还包括反义寡核苷酸、RNA干扰以及基因编辑疗法,在数个相关临床试验中,已展现出突出疗效,其未来发展值得关注。
- 动脉粥样硬化性心血管疾病 /
- 血管生成素样蛋白3 /
- 高脂血症 /
- 调脂治疗
Abstract: Angiopoietin-like protein(ANGPTL3) is a new research hotspot in the field of lipid regulation after PCSK9 inhibitors. In several related clinical trials, it has demonstrated the outstanding efficacy. There are various treatments for this emerging target. In addition to monoclonal antibodies, they also include antisense oligonucleotides, RNAi, and gene editing therapies. The future of ANGPTL3 is worthy of attention.
- atherosclerotic cardiovascular disease /
- angiopoietin-like protein 3 /
- dyslipidemia /
- lipid-lowering therapy

HTML全文

参考文献(15)

[1]	Mach F,Baigent C,Catapano AL,et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J].Eur Heart J,2020,41(1):111-188.
[2]	Grundy SM,Stone NJ,Bailey AL,et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol[J].J Am Coll Cardiol,2019,73(24):e285-e350.
[3]	Genest J.ANGPTL3:a gene,a protein,a new target?aye,there's the rub![J].J Am Coll Cardiol,2017,69(16):2064-2066.
[4]	Aghasizadeh M,Zare-Feyzabadi R,Kazemi T,et al.A haplotype of the ANGPTL3 gene is associated with CVD risk,diabetes mellitus,hypertension,obesity,metabolic syndrome,and dyslipidemia[J].Gene,2021,782:145525.
[5]	Larsen LE,Stoekenbroek RM,Kastelein J,et al.Moving targets:recent advances in lipid-lowering therapies[J].Arterioscler Thromb Vasc Biol,2019,39(3):349-359.
[6]	Stitziel NO,Khera AV,Wang X,et al.ANGPTL3 deficiency and protection against coronary artery disease[J].J Am Coll Cardiol,2017,69(16):2054-2063.
[7]	Gaudet D,Gipe DA,Pordy R,et al.ANGPTL3 inhibition in homozygous familial hypercholesterolemia[J].N Engl J Med,2017,377(3):296-297.
[8]	Tikka A,Jauhiainen M.The role of ANGPTL3 in controlling lipoprotein metabolism[J].Endocrine,2016,52(2):187-193.
[9]	Raal FJ,Rosenson RS,Reeskamp LF,et al.Evinacumab for homozygous familial hypercholesterolemia[J].N Engl J Med,2020,383(8):711-720.
[10]	Jain V,Rifai MA,Mahtta D,et al.Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021:Staying Updated with the Latest Advancements in Prevention[J].Curr Atheroscler Rep,2021,23(9):50.
[11]	Gaudet D,Karwatowska-Prokopczuk E,Baum SJ,et al.Vupanorsen,an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA,lowers triglycerides and atherogenic lipoproteins in patients with diabetes,hepatic steatosis,and hypertriglyceridaemia[J].Eur Heart J,2020,41(40):3936-3945.
[12]	Chadwick AC,Evitt NH,Lv WJ,et al.Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3[J].Circulation,2018,137(9):975-977.
[13]	Gong J,Wang HX,Lao YH,et al.A versatile nonviral delivery system for multiplex gene-editing in the liver[J].Adv Mater,2020 Nov;32(46):e2003537.
[14]	Chiesa ST,Charakida M.High-density lipoprotein function and dysfunction in health and disease[J].Cardiovasc Drugs Ther,2019,33(2):207-219.
[15]	Madsen CM,Varbo A,Nordestgaard BG.Novel insights from human studies on the role of high-density lipoprotein in mortality and noncardiovascular disease[J].Arterioscler Thromb Vasc Biol,2021,41(1):128-140.